N/A
Completed N=207
Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy
Source: ClinicalTrials.gov NCT00357552 ↗Enrolled (actual)
207
Serious AEs
16.3%
Results posted
Sep 2012
Primary outcomePrimary: Percentage of Enrolled Participants With Virologic Success at Week 24 on LPV/r Monotherapy — 87 percentage of enrolled subjects
Summary
Most anti-HIV regimens include a non-nucleoside reverse transcriptase inhibitor (NNRTI); however, some individuals fail on these regimens. The purpose of this study is to evaluate the safety and effectiveness of the protease inhibitor (PI) lopinavir/ritonavir (LPV/r) in HIV infected individuals who are failing an anti-HIV regimen that includes an NNRTI.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Enrolled Participants With Virologic Success at Week 24 on LPV/r Monotherapy |
87 | — |
| PRIMARY Probability of Grade 3 or 4 Sign or Symptom, or Laboratory Toxicity Over 24 Weeks on Study. |
0.23 | — |
| SECONDARY Number of Screened Subjects With at Least One NNRTI, or NRTI-associated Resistance Mutation at A5230 Screening. |
201; 197 | — |
| SECONDARY Time to Treatment Failure, Defined as the First Occurrence of Death, Disease Progression, or Virologic Failure. |
48.0 | — |
| SECONDARY Number of Participants With Study-targeted Diagnoses and Clinical Events |
39 | — |
| SECONDARY Number of Subjects With at Least One New PI-associated Resistance Mutation at Time of Virologic Failure. |
2 | — |
| SECONDARY Percentage of Subjects Reporting Not Skipping Medications in the Last Month. |
90; 86.8; 87.8; 86.2; 86.1; 90.9 | — |
| SECONDARY Time to First New Grade 3 or 4 Sign or Symptom or Laboratory Toxicity Following LPV/r Intensification |
26.0 | — |
| SECONDARY Level of HIV-1 RNA as Ascertained From Paired DBS and Plasma |
0.17; 0.00; 0.83; 0.82; 0.80; 0.80 | — |
| SECONDARY HIV-1 Viral Sequence as Ascertained From Paired DBS and Plasma |
— | — |
| SECONDARY Proportion of Participants With Plasma HIV-1 RNA Levels < 400 Copies/mL From Baseline to Week 104 |
0.02; 0.75; 0.87; 0.84; 0.84; 0.83 | — |
| SECONDARY Change in CD4+ Cell Counts From Study Entry to Week 104 |
213 | — |
Eligibility Criteria
Inclusion Criteria for Step 1 Participants:
- HIV infected
- Continuous treatment with a three-drug, NNRTI-containing regimen for at least 6 months prior to study entry
- Viral load of 1, 000 copies/ml or greater and less or equal to 200,000 copies/ml obtained within 30 days of study entry
- Negative pregnancy test within 48 hours of study entry
- Willing to use acceptable forms of contraception for the duration of the study
- Laboratory values obtained within 30 days of study entry:
- Hemoglobin greater or equal to 8.0 g/dL
- Platelet count greater or equal to 50,000/mm3
- Estimated Creatinine Clearance greater or equal to 60 mL/min x ULN
- AST (SGOT), ALT (SGPT) and alkaline phosphatase < 3 x ULN
- Total bilirubin less or equal to 2.5 x ULN
- Ability and willingness of participant or legal guardian/representative to give informed consent
Inclusion Criteria for Step 2 Participants:
- Virologic failure on LPV/r monotherapy defined as viral load of 400 copies/ml or greater after 24 consecutive weeks on LPV/r monotherapy OR virologic failure after initial viral suppression on LPV/r monotherapy
- Estimated creatinine clearance of 60 ml/min or greater
- Negative pregnancy test within 48 hours of entry into Step 2
- Willing to use acceptable forms of contraception for the duration of the study
Exclusion Criteria for All Participants:
- Breastfeeding
- Known allergy or sensitivity to study drugs
- Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with study adherence to study requirements
- History of chronic hepatitis B infection
Exclusion Criteria for Step I Participants:
- Prior use of any protease inhibitor treatment
- Acute therapy for any serious medical condition within 14 days of study entry. For ongoing or chronic therapy, the participant must be on the treatment regimen for at least 14 days, and clinically stable prior to entry. If a potential participant has TB and has received treatment for more than 2 weeks, the TB treatment would have to be modified to include a rifabutin-containing regimen. TB compatible syndromes will also be carefully evaluated prior to entry.
Exclusion Criteria for Step 2 Participants:
- Active opportunistic infection, including tuberculosis (TB)
Data sourced from ClinicalTrials.gov (NCT00357552). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.